Stool-based DNA testing can help bridge CRC screening gaps between rural and urban populations by providing timely follow-up. The study found no significant difference in follow-up times for ...

Please provide your email address to receive an email when new articles are posted on . The multitarget stool DNA test had a positive predictive value of 31.4% for detecting advanced adenomas.

Patients with an average risk for colorectal cancer (CRC) are candidates for noninvasive tests, such as multitarget stool DNA (mtsDNA), whereas those with a higher risk, including those with a family ...

Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term colorectal cancer (CRC) incidence and ...

An investigational multitarget stool DNA test for screening colorectal cancer detects significantly more cancers than the currently available fecal immunochemical test (FIT), researchers report. But ...

Last week, shares of Cologuard dropped following a U.S. Preventative Services Task Force rating announcement. But, a new study of patient preferences could affect the USPSTF’s final recommendations, ...

A study in World Journal of Gastroenterology investigated whether offering noninvasive multitarget stool DNA tests would improve colorectal cancer screening rates. The researchers identified 393 ...

Millions remain unscreened for colorectal cancer. Learn how noninvasive screening can expand access, preserve capacity, and ...

"Stool-based test offers a promising solution to reduce the burden of a colonoscopy," experts emphasized on September 21st, during the ICG 19 · Metagenomics for Health (ICG19·MH) & The 2nd MOHA ...

For 10% of colorectal cancer patients, hereditary factors play a role, with higher percentages among younger patients.

Please provide your email address to receive an email when new articles are posted on . Implementing computer-aided detection for colonoscopy had “no impact” on the rate of detection for serrated ...

Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? Dear M.N.: When screening patients for ...